New data shows an experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening.
Japanese drugmaker Eisai and its U.S. partner Biogen announced earlier this fall that lecanemab appears to work, a badly needed bright spot after disappointments in the quest for better Alzheimer's treatments.According to the study, the experimental drug appeared to reduce symptoms of the disease by 27%.
In The New England Journal of Medicine, results from a phase 3 trial showed that in a group study, patients who took the drug showed less cognitive and functional decline compared to those who took a placebo. Those who participated in the study complained of side effects, including brain swelling, bleeding, and headaches.
Eisai says the drug's benefit translates to about a five-month delay in progression over the 18-month study.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
New Alzheimer’s drug shows promise in slowing disease but may contain significant risks, study showsAn experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers report — but it remains unclear how much difference that might make in people’s lives.
Leer más »
DOJ: Bothell drug dealer sentenced 10 years for involvement in 2020 drug ring takedownA Bothell man who was involved in a major drug ring bust in 2020 was sentenced to 10 years in prison on Tuesday, according to the U.S. Department of Justice (DOJ). FOX13
Leer más »
Drug slows Alzheimer's but can it make a real difference?New data shows an experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening. health Alzheimers kprc2 click2houston
Leer más »
New Alzheimer’s Drug Shows Positive Results but Side EffectsA new Alzheimer’s drug slowed cognitive decline in a study, but caused brain bleeds and swelling in some patients, furthering debate about its usefulness
Leer más »
New data shows Alzheimer's drug can slow cognitive declineResearchers followed nearly 1,800 patients over the course of 18 months and found the drug 'resulted in moderately less decline on measures of cognition and function,' compared to patients who received a placebo.
Leer más »
Drug slows Alzheimer's but can it make a real difference?New data shows an experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening.
Leer más »